World ADC Berlin

The approval of Besponsa and re-approval of Mylotarg has fuelled the belief that ADCs are at the forefront of research in the war to fight cancer. With a further 72 ADCs in clinical development this means ADCs are putting cancer treatment on the cusp of a major breakthrough.

These huge strides forward and more will be covered at World ADC Berlin.

Now in it’s 8th year, World ADC Berlin is Europe’s longest standing and most comprehensive antibody-drug conjugate conference. Attend this meeting to develop more clinically efficacious and safe ADCs.